Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
312.40
-3.40 (-1.08%)
Feb 21, 2025, 5:29 PM CET
STO:SOBI Revenue
In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B SEK with 17.65% growth. Swedish Orphan Biovitrum AB had revenue of 7.44B in the quarter ending December 31, 2024, with 8.67% growth.
Revenue
26.03B
Revenue Growth
+17.65%
P/S Ratio
4.10
Revenue / Employee
14.15M
Employees
1,840
Market Cap
107.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Getinge AB | 34.76B |
Sectra AB | 3.14B |
Camurus AB | 1.87B |
Medicover AB | 23.97B |
Vitrolife AB | 3.61B |
Elekta AB | 17.72B |
Vimian Group AB | 4.29B |
BioArctic AB | 257.35M |
Swedish Orphan Biovitrum AB News
- 17 days ago - Swedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancements - Seeking Alpha
- 17 days ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Swedish Orphan Biovitrum AB (publ) 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) - PRNewsWire
- 4 months ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases - Benzinga
- 7 months ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 10 months ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript - Seeking Alpha